Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with histologically confirmed stage I to III invasive breast cancer with estrogen receptor and/or progesterone receptor-positive, HER2/neu-negative receptor status were included.
|
30852142 |
2019 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of analytical and immunohistochemical performance of progesterone receptor (PR) antibodies with correlation to recurrence of invasive breast cancer treated with endocrine therapy.
|
29758480 |
2018 |
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, HER-2-positive expression and high Ki-67 expression are predictors of LVI, whereas the expression of ER, PR, CK5/6, EGFR, VEGF, E-cadherin, BCL11A and P53 is not associated with LVI in invasive breast cancer.
|
29416785 |
2018 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the correlation between lymphovascular invasion (LVI) and tumor size, histological grade, and the expression statuses of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki67, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), E-cadherin, and P53 in invasive breast cancer, then establish a prediction model of LVI based on the associated clinicopathological factors.A total of 392 patients with primary invasive breast cancers were enrolled, and their paraffin-embedded tissues were manufactured into the tissue microarray.
|
30412123 |
2018 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both TBR and SUVmax were significantly correlated with tumor size, incidence of axillary lymph node metastasis, histologic grade, estrogen receptor, progesterone receptor status, and Ki-67.There is a moderate degree of association between TBR of sestamibi and SUVmax of FDG in the invasive breast cancer.
|
30412075 |
2018 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data of 261 patients who had pathologically confirmed estrogen or progesterone receptor positive invasive breast cancer and had received hormonotherapy for at least a 5-year period were retrospectively analyzed.
|
30426082 |
2018 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma.
|
30196425 |
2018 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The potential impact of androgens on mammary carcinogenesis has been studied in recent years, and several authors have proposed androgen receptor (AR) IHC testing and targeted antiandrogenic therapy in patients with locally advanced or metastatic triple-negative invasive breast cancer (ie, negative for ER and progesterone receptor and HER-2).
|
29489512 |
2018 |
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The number of PR positive epithelial cells was significantly lower in the group of women with early pregnancy and no subsequent breast cancer compared to the group of nulliparous women with subsequent invasive breast cancer (p = 0.0135).
|
28423605 |
2017 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, using an immunohistochemical method, 272 patients with invasive breast cancer were assessed for the expression of CHIP (graded scores 0-3) and the statuses of biomarkers, such as estrogen receptor (ER), progesterone receptor (PgR), and HER2.
|
27334118 |
2016 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to compare the estrogen receptor, progesterone receptor and HER2 status as determined by the MapQuant™ test to the routine immuno-histochemical tests in early stage invasive breast cancer in a large comprehensive cancer center.
|
26829108 |
2016 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
|
26650824 |
2016 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed data from 887 patients with invasive breast cancer and observed that increased Wnt and histone deacetylase (HDAC) activities are associated with estrogen receptor 1 (ESR1) and progesterone receptor (PGR) repression, poor survival, and increased relapse.
|
27859250 |
2016 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.
|
25560175 |
2015 |
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Progesterone receptor (PR) expression assessment in early invasive breast cancer remains controversial.
|
24300977 |
2014 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
As part of an ongoing quality assurance study, this study evaluated the relationship between Oncotype DX recurrence score and progesterone receptor immunohistochemical result within each Nottingham tumor grade in 1074 cases of invasive breast carcinoma for which an Oncotype DX recurrence score was available.
|
23060300 |
2013 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status have a strong prognostic and predictive value in invasive breast carcinoma (IBC).
|
22298467 |
2012 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oestrogen receptor (ER), progesterone receptor (PR), HER2, ki67, p53 and DNA ploidy was performed by image analysis in 162 consecutive IBCAs in women (≤ 40 years) and compared with women ≥ 50 years (100 cases).
|
22713661 |
2012 |
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To evaluate polysomy/amplification of Cep17 in invasive breast cancer with relation to proliferative activity (Ki-67), estrogen receptor, progesterone receptor, and HER2/ neu status, in an attempt to identify a subgroup of patients with a worse prognosis.
|
22938586 |
2012 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of estrogen receptor (ER), progesterone receptor (PR), HER2, HER4, and cystatin M was retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (DCIS) and in 175 patients with invasive breast cancer (IBC).
|
21092257 |
2010 |
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Increased expression of steroid receptors in LCIS suggests their possible role in the biology of LCIS and, for PR, could influence the predisposition of women diagnosed with LCIS to develop invasive breast carcinoma.
|
19309393 |
2009 |
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
|
10914818 |
2000 |
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.
|
10403901 |
1999 |